• Lumiracoxib;
  • COX-2;
  • cyclooxygenase-2 selective inhibitor;
  • preclinical
  • 1
    This manuscript presents the preclinical profile of lumiracoxib, a novel cyclooxygenase-2 (COX-2) selective inhibitor.
  • 2
    Lumiracoxib inhibited purified COX-1 and COX-2 with Ki values of 3 and 0.06 μM, respectively. In cellular assays, lumiracoxib had an IC50 of 0.14 μM in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 μM (HEK 293 cells transfected with human COX-1).
  • 3
    In a human whole blood assay, IC50 values for lumiracoxib were 0.13 μM for COX-2 and 67 μM for COX-1 (COX-1/COX-2 selectivity ratio 515).
  • 4
    Lumiracoxib was rapidly absorbed following oral administration in rats with peak plasma levels being reached between 0.5 and 1 h.
  • 5
    Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B2 (TxB2) generation with an ID50 of 33 mg kg−1, whereas COX-2-derived production of prostaglandin E2 (PGE2) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID50 value of 0.24 mg kg−1.
  • 6
    Efficacy of lumiracoxib in rat models of hyperalgesia, oedema, pyresis and arthritis was dose-dependent and similar to diclofenac. However, consistent with its low COX-1 inhibitory activity, lumiracoxib at a dose of 100 mg kg−1 orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05).
  • 7
    Lumiracoxib is a highly selective COX-2 inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety.

British Journal of Pharmacology (2005) 144, 538–550. doi:10.1038/sj.bjp.0706078